These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33581698)

  • 1. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
    Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
    Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jiménez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pollio B; Sigaud M; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
    Mathias M; Abashidze M; Abraham A; Belletrutti MJ; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Lambert T; Kavardakova N; Lohade S; Turea V; Wu JKM; Klukowska A
    Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2017 Mar; 16(3):405-410. PubMed ID: 28103444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, efficacy and safety of Nuwiq
    Liesner RJ; Abashidze M; Aleinikova O; Altisent C; Belletrutti MJ; Borel-Derlon A; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Fouzia NA; Gattens M; Gruel Y; Guillet B; Kavardakova N; El Khorassani M; Klukowska A; Lambert T; Lohade S; Sigaud M; Turea V; Wu JKM; Vdovin V; Pavlova A; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Haemophilia; 2018 Mar; 24(2):211-220. PubMed ID: 28815880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simoctocog alfa (Nuwiq
    Klukowska A; Sidonio RF; Young G; Mancuso ME; Álvarez-Román MT; Bhatnagar N; Jansen M; Knaub S
    Ther Adv Hematol; 2024; 15():20406207241245511. PubMed ID: 38737006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.
    Lissitchkov T; Klukowska A; Pasi J; Kessler CM; Klamroth R; Liesner RJ; Belyanskaya L; Walter O; Knaub S; Bichler J; Jansen M; Oldenburg J
    Ther Adv Hematol; 2019; 10():2040620719858471. PubMed ID: 31263528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.
    Vepsäläinen K; Lassila R; Arola M; Huttunen P; Koskinen S; Ljung R; Lähteenmäki P; Möttönen M; Riikonen P
    Haemophilia; 2016 Sep; 22(5):721-9. PubMed ID: 27339837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Nuwiq
    Zozulya N; Kessler CM; Klukowska A; von Depka M; Hampton K; Hay CRM; Jansen M; Bichler J; Knaub S; Rangarajan S
    Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
    Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
    Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
    Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
    Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
    Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
    Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.